Update shared on 11 Sep 2025
Fair value Increased 14%Analysts have raised their price target for Gossamer Bio from $7.75 to $8.86, citing optimism for seralutinib's novel mechanism and market potential in pulmonary hypertension as key drivers.
Analyst Commentary
- Positive outlook on Gossamer Bio's strategy in targeting pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- Optimism regarding the lead asset, seralutinib, due to its novel mechanism of action as an inhaled tyrosine kinase inhibitor.
- Expectation of significant market uptake for seralutinib.
- Belief that seralutinib could serve as an adjunct to standard of care.
- Preference for the company's overall approach in these indications.
What's in the News
- Gossamer Bio was added to multiple Russell indices, including the Russell 2000, 2500, 3000, Microcap, and Small Cap Completeness indices, as well as their respective growth and dynamic benchmarks.
- The company completed enrollment for the global Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients, with topline results expected in February 2026.
- The PROSERA trial is a double-blind, placebo-controlled, global registrational trial, with 390 patients randomized 1:1 to seralutinib or placebo, and uses enrichment criteria to optimize patient selection.
- The study is being jointly developed between Gossamer Bio and the Chiesi Group under a global collaboration agreement.
Valuation Changes
Summary of Valuation Changes for Gossamer Bio
- The Consensus Analyst Price Target has significantly risen from $7.75 to $8.86.
- The Future P/E for Gossamer Bio has significantly risen from 78.56x to 98.84x.
- The Net Profit Margin for Gossamer Bio has significantly fallen from 16.06% to 14.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.